BRCA2 and cancer: Numerous studies have established that cancers with a dysfunction of the HR DNA repair pathway, also referred to as “BRCAness,” share characteristics with BRCA1- or BRCA2-mutated cancer cells and are very sensitive to PARPi [40, 41].